Exelixis announces results of study evaluating cabozantinib in mCRPC treatment

Exelixis announced detailed results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib or CABOMETYX in combination with atezolizumab compared with a second novel hormonal therapy NHT in patients with metastatic castration-resistant prostate cancer or mCRPC, and measurable extra-pelvic soft tissue disease who have progressed on one prior NHT. The detailed findings are being presented during Oral Abstract Session A: Prostate Cancer on January 25 at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium or ASCO…”Patients with metastatic castration-resistant prostate cancer with prior progression on a novel hormone therapy and who have measurable soft tissue metastasis experience the worst outcomes among advanced prostate cancer patients and have limited treatment options,” said Neeraj Agarwal, M.D., FASCO, Senior Director for Clinical Research at Huntsman Cancer Institute at the University of Utah I am encouraged by these results and the potential for cabozantinib plus atezolizumab to be a widely available treatment option for our patients.” As announced in August 2023, CONTACT-02 met one of its primary endpoints, demonstrating a statistically significant improvement in progression-free survival PFS as assessed by a blinded independent radiology committee BIRC and per RECIST 1.1. The PFS analysis was conducted in the first 400 randomized patients in the intent-to-treat, PFS ITT, population and per protocol. Similar results were observed for all patients.